New report says multiple sclerosis drugs are overpriced
At least 400,000 Americans have multiple sclerosis, and they are paying too much for their drugs to treat the condition, according to a new report from the Institute for Clinical and Economic Review.
ICER, a not-for-profit group that the pharmaceutical industry loathes, attempts to identify the cost effectiveness of drugs. Many of the multiple sclerosis drugs ICER studied are clinically effective. But the group's president, Dr. Steven Pearson, said in a statement that "high prices and regular price increases contribute significantly to restrictions on coverage and access that make it difficult for patients to get the medications they need." Multiple sclerosis drugs cost between $63,000 per year and more than $100,000 per year.
Companies in the crosshairs that make multiple sclerosis drugs: AbbVie, Bayer, Biogen, Genentech, Merck, Novartis, Sanofi, and Teva Pharmaceutical Industries.